Jazz Pharmaceuticals (JAZZ) 10-Q 5 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 29, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'JAZZ	'
Entity Registrant Name	'Jazz Pharmaceuticals plc	'
Entity Central Index Key	'0001232524	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	57,789,719

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$588,462	$387,196
Accounts receivable, net	113,271	75,480
Inventories	24,868	26,525
Prepaid expenses	19,350	7,445
Deferred tax assets, net	45,565	35,813
Other current assets	18,551	19,113
Total current assets	810,067	551,572
Property and equipment, net	12,060	7,281
Intangible assets, net	823,724	869,952
Goodwill	446,823	442,600
Deferred tax assets, net, non-current	70,976	74,850
Deferred financing costs	15,458	16,576
Other non-current assets	6,391	3,662
Total assets	2,185,499	1,966,493
Current liabilities:	'	'
Accounts payable	22,434	15,887
Accrued liabilities	106,390	104,666
Current portion of long-term debt	5,572	29,688
Income taxes payable	19,850	39,884
Contingent consideration	47,700	0
Contingent consideration	0	34,800
Deferred tax liability, net	275	275
Deferred revenue	1,138	1,138
Total current liabilities	203,359	191,538
Deferred revenue, non-current	6,001	6,776
Long-term debt, less current portion	545,564	427,073
Deferred tax liability, net, non-current	170,127	178,393
Other non-current liabilities	16,747	6,621
Commitments and contingencies (Note 7)	'	'
Shareholders’ equity:	'	'
Ordinary shares	6	6
Non-voting euro deferred shares	55	55
Capital redemption reserve	471	471
Additional paid-in capital	1,201,221	1,151,010
Accumulated other comprehensive income	44,622	31,046
Accumulated deficit	-2,674	-61,296
Total shareholders’ equity	1,243,701	1,121,292
Total liabilities and shareholders’ equity	$2,185,499	$1,966,493

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Product sales, net	$230,386	$174,130	$631,602	$398,585
Royalties and contract revenues	1,774	1,385	5,047	3,691
Total revenues	232,160	175,515	636,649	402,276
Operating expenses:	'	'	'	'
Cost of product sales (excluding amortization of acquired developed technologies)	24,252	32,629	76,503	52,662
Selling, general and administrative	74,970	60,924	223,004	162,505
Research and development	12,814	6,920	32,811	13,200
Intangible asset amortization	19,564	19,742	58,518	43,444
Total operating expenses	131,600	120,215	390,836	271,811
Income from operations	100,560	55,300	245,813	130,465
Interest expense, net	-6,202	-7,750	-20,743	-9,199
Foreign currency loss	-614	-1,099	-728	-1,357
Loss on extinguishment and modification of debt	0	0	-3,749	0
Income from continuing operations before income tax provision	93,744	46,451	220,593	119,909
Income tax provision	18,335	12,856	59,574	24,966
Income from continuing operations	75,409	33,595	161,019	94,943
Loss from discontinued operations	0	-386	0	-6,908
Net income	$75,409	$33,209	$161,019	$88,035
Basic income (loss) per ordinary share:	'	'	'	'
Income from continuing operations (in dollars per share)	$1.30	$0.59	$2.76	$1.69
Loss from discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.12)
Net income (in dollars per share)	$1.30	$0.58	$2.76	$1.57
Diluted income (loss) per ordinary share:	'	'	'	'
Income from continuing operations (in dollars per share)	$1.23	$0.56	$2.62	$1.59
Loss from discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.12)
Net income (in dollars per share)	$1.23	$0.55	$2.62	$1.47
Weighted-average ordinary shares used in per share computations:	'	'	'	'
Basic (in shares)	58,217	57,703	58,437	56,198
Diluted (in shares)	61,519	60,883	61,532	59,846

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net income	$75,409	$33,209	$161,019	$88,035
Other comprehensive income:	'	'	'	'
Foreign currency translation adjustments	25,402	14,248	13,576	13,860
Available-for-sale securities:	'	'	'	'
Net unrealized gain on available-for-sale securities, net of income taxes	0	0	0	8
Reclassification adjustments for gains included in earnings, net of income taxes	0	0	0	23
Other comprehensive income	25,402	14,248	13,576	13,891
Total comprehensive income	100,811	47,457	174,595	101,926
Continuing Operations [Member]	'	'	'	'
Available-for-sale securities:	'	'	'	'
Total comprehensive income	100,811	47,843	174,595	108,834
Discontinued Operations [Member]	'	'	'	'
Available-for-sale securities:	'	'	'	'
Total comprehensive income	$0	($386)	$0	($6,908)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities	'	'
Net income	$161,019	$88,035
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Amortization of intangible assets	58,518	51,014
Depreciation	2,065	789
Loss on disposal of property and equipment	47	146
Share-based compensation	32,139	15,151
Excess tax benefit from share-based compensation	-82	-4,266
Acquisition accounting inventory fair value step-up	3,143	17,822
Change in fair value of contingent consideration	12,900	1,100
Deferred income taxes	-17,962	-8,768
Provision for losses on accounts receivable and inventory	1,758	2,696
Loss on extinguishment and modification of debt	3,749	0
Other non-cash transactions	4,435	1,771
Changes in assets and liabilities:	'	'
Accounts receivable	-37,649	-17,773
Inventories	-3,445	1,715
Prepaid expenses and other current assets	-11,300	-3,843
Other long-term assets	-3,421	-2,297
Accounts payable	6,670	-2,543
Accrued liabilities	1,562	-15,812
Income taxes payable	-19,086	28,139
Deferred revenue	-776	-48
Other non-current liabilities	10,125	-301
Liability under government settlement	0	-7,320
Net cash provided by operating activities	204,409	145,407
Investing activities	'	'
Acquisitions, net of cash acquired	0	-542,531
Purchases of marketable securities	0	-37,443
Proceeds from sale of marketable securities	0	81,246
Proceeds from maturities of marketable securities	0	31,988
Acquisition of intangible assets	-1,300	0
Purchases of property and equipment	-6,874	-4,993
Purchase of product rights	0	-10,750
Net cash used in investing activities	-8,174	-482,483
Financing activities	'	'
Net proceeds from issuance of debt	553,425	450,916
Proceeds from employee equity incentive and purchase plans and exercise of warrants	23,577	20,995
Share repurchases	-102,397	0
Payment of employee withholding taxes related to share-based awards	-5,303	-25,299
Excess tax benefit from share-based compensation	82	4,266
Repayment of long-term debt	-464,517	-5,938
Net cash provided by financing activities	4,867	444,940
Effect of exchange rates on cash and cash equivalents	164	-147
Net increase in cash and cash equivalents	201,266	107,717
Cash and cash equivalents, at beginning of period	387,196	82,076
Cash and cash equivalents, at end of period	$588,462	$189,793

The_Company_and_Summary_of_Sig

The Company and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
The Company and Summary of Significant Accounting Policies	'
	The Company and Summary of Significant Accounting Policies
	Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland, is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing innovative products that address unmet medical needs. Our strategy is to continue to create shareholder value by:
	•	Growing sales of the existing products in our portfolio, including by identifying new growth opportunities;
	•	Acquiring additional marketed specialty products or products close to regulatory approval to leverage our existing expertise and infrastructure; and
	•	Pursuing targeted development of a pipeline of post-discovery specialty product candidates.
	On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma Public Limited Company, or Azur Pharma, were combined in a merger transaction, or the Azur Merger, accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with Jazz Pharmaceuticals, Inc. treated as the acquiring company for accounting purposes. As part of the Azur Merger, a wholly-owned subsidiary of Azur Pharma merged with and into Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. surviving the Azur Merger as a wholly-owned subsidiary of Jazz Pharmaceuticals plc. Prior to the Azur Merger, Azur Pharma changed its name to Jazz Pharmaceuticals plc.
	On June 12, 2012, we completed the acquisition of EUSA Pharma Inc., or EUSA Pharma, which we refer to as the EUSA Acquisition.
	Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries, including its predecessor Jazz Pharmaceuticals, Inc. All references to “Azur Pharma” are references to Jazz Pharmaceuticals plc (f/k/a Azur Pharma Public Limited Company) and its consolidated subsidiaries prior to the effective time of the Azur Merger on January 18, 2012. All references to “EUSA Pharma” are references to EUSA Pharma Inc. and its consolidated subsidiaries prior to the effective time of the EUSA Acquisition on June 12, 2012.
	Basis of Presentation
	These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the annual consolidated financial statements and accompanying notes of Jazz Pharmaceuticals plc included in its Annual Report on Form 10-K for the year ended December 31, 2012. The results of operations of the acquired Azur Pharma and EUSA Pharma businesses, along with the estimated fair values of the assets acquired and liabilities assumed in each transaction, have been included in our condensed consolidated financial statements since the effective dates of the Azur Merger and the EUSA Acquisition, respectively.
	In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013, for any other interim period or for any future period.
	Certain prior period amounts presented in the accompanying footnotes have been reclassified to conform to current period presentation, as described in Note 2.
	These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our wholly-owned subsidiaries and intercompany transactions and balances have been eliminated.
	Significant Risks and Uncertainties
	Our financial results are significantly influenced by sales of Xyrem® (sodium oxybate) oral solution. Maintaining or increasing sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition, changed or increased regulatory restrictions, and continued acceptance of Xyrem as safe and effective by physicians and patients. Two abbreviated new drug applications, or ANDAs, have been filed with the United States Food and Drug Administration, or FDA, by third parties seeking to market generic versions of Xyrem. We have sued both third parties for infringement of our patents, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	We are continuing our efforts on various regulatory matters, including working with the FDA on updated documents that we have submitted to the FDA on our risk management and controlled distribution system for Xyrem, which we refer to as the Xyrem Risk Management Program, and potential modifications to this program. We are engaged in ongoing communications with the FDA with respect to our risk evaluation and mitigation strategies, or REMS, documents for Xyrem, but we have not reached agreement on certain significant terms. For example, we disagree with the FDA’s current position that, as part of the current REMS process, the Xyrem deemed REMS should be modified to enable the distribution of Xyrem through more than one pharmacy. We expect that final REMS documents for Xyrem will include modifications to, and/or requirements that are not currently implemented in, the Xyrem Risk Management Program. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors to enter the market and/or negatively affect sales of Xyrem. We cannot predict whether, or on what terms, we will reach agreement with FDA on final REMS documents for Xyrem, whether we will initiate dispute resolution or other proceedings with FDA prior to finalizing the REMS documents, or, if any such proceedings are initiated, the outcome or timing thereof.
	In addition, the FDA is seeking to schedule an initial meeting with us and ANDA applicants to facilitate the development of a single shared system REMS for Xyrem (sodium oxybate). Also, we may face pressure to license or share our Xyrem Risk Management Program, which is the subject of multiple issued patents, or elements of it, with generic competitors. We cannot predict the outcome or impact on our business of any discussions with the FDA and/or any ANDA applicant with respect to the potential creation of a single shared system REMS for Xyrem, any future action that may be taken by a third party to seek to license or share our REMS, or the FDA’s response to a certification that a third party has been unable to obtain a license.
	Our financial results are increasingly influenced by sales of our second largest product, Erwinaze® (asparaginase Erwinia chrysanthemi), which have continued to grow. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available through ongoing research and development activities. However, our ability to successfully and sustainably grow sales of Erwinaze is subject to a number of risks and uncertainties, including assuring sufficient supply of Erwinaze on a timely basis, the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli-derived asparaginase within that population, and our need to apply for and receive marketing authorizations in certain additional countries so we can launch promotional efforts in those countries. We maintain very limited inventory of Erwinaze and, in 2013, our supply of Erwinaze was nearly completely absorbed by demand for the product. While we have been able to resolve potential supply shortages and meet product demand to date, if our continued efforts to avoid supply shortages are not successful, we could experience Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product.
	In addition to risks related specifically to Xyrem and Erwinaze, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly because we maintain limited inventories of certain products, including products for which our supply demands are growing, and we are dependent on single source suppliers to continue to meet our ongoing commercial needs; the need to obtain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to health care cost containment and other austerity measures in the United States and worldwide; the ongoing regulation and oversight by the FDA, the U.S. Drug Enforcement Administration, or DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals; the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance of our products by patients, physicians and payors; and the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval. Other risks and uncertainties related to our ability to execute on our strategy include: our ability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations.
	Concentrations of Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist of cash equivalents and marketable securities. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.
	We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to hospitals, pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of September 30, 2013, five customers accounted for 88% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, which accounted for 73% of gross accounts receivable, and Accredo Health Group, Inc., or Accredo, which accounted for 7% of gross accounts receivable. As of December 31, 2012, five customers accounted for 78% of gross accounts receivable, including Express Scripts, which accounted for 51% of gross accounts receivable, and Accredo, which accounted for 11% of gross accounts receivable.
	We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
	Net Income per Ordinary Share
	Basic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Numerator:
	Income from continuing operations	$	75,409		$	33,595		$	161,019	$	94,943
	Loss from discontinued operations	—			(386		)	—		(6,908		)
	Net income	$	75,409		$	33,209		$	161,019	$	88,035
	Denominator:
	Weighted-average ordinary shares - basic	58,217			57,703			58,437		56,198
	Dilutive effect of employee equity incentive and purchase plans	1,852			1,404			1,587		1,557
	Dilutive effect of warrants	1,450			1,776			1,508		2,091
	Weighted-average ordinary shares - diluted	61,519			60,883			61,532		59,846
	Basic income (loss) per ordinary share:
	Income from continuing operations	$	1.3		$	0.59		$	2.76	$	1.69
	Loss from discontinued operations	—			(0.01		)	—		(0.12		)
	Net income	$	1.3		$	0.58		$	2.76	$	1.57
	Diluted income (loss) per ordinary share:
	Income from continuing operations	$	1.23		$	0.56		$	2.62	$	1.59
	Loss from discontinued operations	—			(0.01		)	—		(0.12		)
	Net income	$	1.23		$	0.55		$	2.62	$	1.47
	Potentially dilutive ordinary shares from employee equity plans and warrants are determined by applying the treasury stock method to the assumed exercise of warrants and share options, the assumed vesting of outstanding restricted stock units, or RSUs, and the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP. The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013		2012			2013		2012
	Options to purchase ordinary shares and RSUs	1,028		1,785			2,074		1,314
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, or ASU No. 2013-11, which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. ASU No. 2013-11 will be effective for us beginning January 1, 2014. We do not anticipate that the adoption of this standard will have a material impact on our financial position.
	In March 2013, the FASB issued ASU No. 2013-05, “Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”, or ASU No. 2013-05. The objective of ASU No. 2013-05 is to resolve the diversity in practice regarding the release into net income of the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. ASU No. 2013-05 will be effective for us beginning January 1, 2014. We do not anticipate that the adoption of this standard will have a material impact on our results of operations or financial position, absent any material transactions involving the derecognition of subsidiaries or groups of assets within a foreign entity.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consisted of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Raw materials	$	4,474	$	4,979
	Work in process	6,523		5,410
	Finished goods	13,871		16,136
	Total inventories	$	24,868	$	26,525
	Inventories of $4.2 million previously classified as raw materials as of December 31, 2012 have been reclassified to work in process to conform to current period presentation. As of September 30, 2013 and December 31, 2012, the fair value of inventories acquired included a step-up in the value of inventories of $0.8 million and $4.0 million, respectively.

Fair_Value_Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurement	'
	Fair Value Measurement
	Cash and cash equivalents consisted of the following (in thousands):
		30-Sep-13
		Amortized		Gross		Gross		Estimated		Cash and		Marketable
		Cost		Unrealized		Unrealized		Fair Value		Cash		Securities
				Gains		Losses				Equivalents
	Cash	$	295,970	$	—	$	—	$	295,970	$	295,970	$	—
	Time deposits	292,492		—		—		292,492		292,492		—
	Totals	$	588,462	$	—	$	—	$	588,462	$	588,462	$	—
		31-Dec-12
		Amortized		Gross		Gross		Estimated		Cash and		Marketable
		Cost		Unrealized		Unrealized		Fair Value		Cash		Securities
				Gains		Losses				Equivalents
	Cash	$	343,548	$	—	$	—	$	343,548	$	343,548	$	—
	Money market funds	43,648		—		—		43,648		43,648		—
	Totals	$	387,196	$	—	$	—	$	387,196	$	387,196	$	—
	Cash equivalents are considered available-for-sale. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income. All available-for-sale securities held as of September 30, 2013 and December 31, 2012 were cash equivalents.
	The following table summarizes, by major security type, our available-for-sale securities and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
		30-Sep-13								31-Dec-12
		Quoted		Significant Other		Significant		Total		Quoted		Significant		Total
		Prices in		Observable		Unobservable		Estimated		Prices in		Unobservable		Estimated
		Active		Inputs		Inputs		Fair Value		Active		Inputs		Fair Value
		Markets for		(Level 2)		(Level 3)				Markets for		(Level 3)
		Identical								Identical
		Assets								Assets
		(Level 1)								(Level 1)
	Assets:
	Available-for-sale securities
	Time deposits	$	—	$	292,492	$	—	$	292,492	$	—	$	—	$	—
	Money market funds	—		—		—		—		43,648		—		43,648
	Totals	$	—	$	292,492	$	—	$	292,492	$	43,648	$	—	$	43,648
	Liabilities:
	Contingent consideration	$	—	$	—	$	47,700	$	47,700	$	—	$	34,800	$	34,800
	As of September 30, 2013, our available-for-sale securities included time deposits and their carrying values were approximately equal to their fair values. As of December 31, 2012, our available-for-sale securities included money market funds. There were no transfers between the different levels of the fair value hierarchy in 2013 or in 2012.
	As part of the EUSA Acquisition, we agreed to make an additional contingent payment of $50.0 million in cash if Erwinaze achieves U.S. net sales of $124.5 million or greater in 2013. The fair value measurement of this contingent consideration obligation is determined using unobservable Level 3 inputs. These inputs include the probability of 2013 U.S. net sales of Erwinaze equaling or exceeding the $124.5 million threshold and the discount rate. A significant increase or decrease in the estimated probability of meeting the milestone threshold would result in a significantly higher or lower fair value measurement, respectively. The range of the estimated contingent payment is from zero if 2013 U.S. net sales of Erwinaze are less than $124.5 million to $50.0 million if 2013 U.S. net sales of Erwinaze equal or exceed $124.5 million.
	The change in fair value of the contingent consideration payable was estimated as follows (in thousands):
		Level 3
	Balance at December 31, 2012	$	34,800
	Fair value adjustment recorded within selling, general and administrative expenses	12,900
	Balance at September 30, 2013	$	47,700
	In 2013, the fair value adjustment reflects a change in the estimated probability of meeting the milestone threshold and the impact of discounting as a result of the passage of time.
	As of September 30, 2013, the estimated fair value of the $555.8 million principal amount of our new term loans was $555.1 million and the carrying amount was $551.1 million. The fair value was determined using quotes from the administrative agent of our credit facility that are based on the bid/ask prices of our new term loans (Level 2). For additional information related to our new term loans, see Note 6.

Certain_Balance_Sheet_Items

Certain Balance Sheet Items	9 Months Ended
	Sep. 30, 2013
Certain Balance Sheet Items [Abstract]	'
Certain Balance Sheet Items	'
	Certain Balance Sheet Items
	Property and equipment consisted of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Computer software	$	7,670		$	4,292
	Computer equipment	5,059			3,687
	Leasehold improvements	4,303			3,899
	Construction-in-progress	2,638			1,135
	Furniture and fixtures	1,966			1,953
	Machinery and equipment	186			94
	Subtotal	21,822			15,060
	Less accumulated depreciation and amortization	(9,762		)	(7,779		)
	Property and equipment, net	$	12,060		$	7,281
	Accrued liabilities consisted of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Rebates and other sales deductions	$	37,125		$	29,235
	Employee compensation and benefits	26,263			24,900
	Sales returns reserve	21,756			26,385
	Royalties	3,139			3,271
	Professional fees	1,944			2,163
	Other	16,163			18,712
	Total accrued liabilities	$	106,390		$	104,666

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	The gross carrying amount of goodwill was as follows (in thousands):
	Balance at December 31, 2012	$	442,600
	Foreign exchange	4,223
	Balance at September 30, 2013	$	446,823
	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):
		September 30, 2013									December 31, 2012
		Remaining		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Weighted-		Carrying		Amortization			Value		Carrying		Amortization			Value
		Average Useful		Amount							Amount
		Life
		(In years)
	Acquired developed technologies	11.7		$	946,595	$	(157,423	)	$	789,172	$	930,834	$	(97,578	)	$	833,256
	Trademarks	1.3		2,600		(2,259		)	341		2,600		(2,054		)	546
	Total finite-lived intangible assets			949,195		(159,682		)	789,513		933,434		(99,632		)	833,802
	Acquired IPR&D assets			34,211		—			34,211		36,150		—			36,150
	Total intangible assets			$	983,406	$	(159,682	)	$	823,724	$	969,584	$	(99,632	)	$	869,952
	Based on finite-lived intangible assets recorded as of September 30, 2013, and assuming the underlying assets will not be impaired in the future and that we will not change the expected lives of the assets, future amortization costs were estimated as follows (in thousands):
	Year Ending December 31,	Estimated
		Amortization
		Expense
	2013 (remainder)	$	19,872
	2014	79,284
	2015	73,238
	2016	68,908
	2017	68,816
	Thereafter	479,395
	Total	$	789,513

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-term Debt	'
	Long-Term Debt
	Amendment of Credit Facility and Term Loan Refinancing
	On June 13, 2013, Jazz Pharmaceuticals plc, as guarantor, and certain of its wholly-owned subsidiaries, as borrowers, entered into an amendment of our original credit agreement, dated as of June 12, 2012, with Barclays Bank PLC, as administrative agent, and certain other lenders.
	The amended credit agreement provides for $557.2 million principal amount of new term loans and a new revolving credit facility of $200.0 million that replaced the revolving credit facility of $100.0 million provided for under the original credit agreement. We used a portion of the proceeds from the new term loans to refinance in full the outstanding term loans under the original credit agreement in an aggregate principal amount of $457.2 million, or the original term loans. The new term loans have the same June 12, 2018 maturity date that was applicable to the original term loans. Future loans under the new revolving credit facility, if any, will have the same June 12, 2017 maturity date that was applicable under the original credit agreement.
	The new term loans bear interest, at our option, at a rate equal to either the LIBOR rate, plus an applicable margin of 2.75% per annum (subject to a 0.75% LIBOR floor), or the prime lending rate, plus an applicable margin equal to 1.75% per annum (subject to a 1.75% prime rate floor). Borrowings under the new revolving credit facility bear interest, at our option, at a rate equal to either the LIBOR rate, plus an applicable margin of 2.50% per annum, or the prime lending rate, plus an applicable margin equal to 1.50% per annum, subject to reduction by 0.25% or 0.50% based upon our secured leverage ratio. The new revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.25% to 0.50% per annum based upon our secured leverage ratio.
	The borrowers’ obligations under the amended credit agreement and any hedging or cash management obligations entered into with a lender or an affiliate of a lender are guaranteed by Jazz Pharmaceuticals plc and certain of its subsidiaries, referred to below as restricted subsidiaries, and are secured by substantially all of their assets.
	We may make voluntary prepayments of principal at any time without payment of a premium, except that a 1% premium would apply to any repricing of the new term loans effected on or prior to December 13, 2013. We are required to make mandatory prepayments of the new term loans (without payment of a premium) with (1) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (2) net cash proceeds from issuances of debt (other than certain permitted debt), (3) beginning with the fiscal year ending December 31, 2014, 50% of our excess cash flow as defined in the amended credit agreement (subject to decrease to 25% if our secured leverage ratio is equal to or less than 2.25 to 1.00 and greater than 1.25 to 1.00 or 0% if our secured leverage ratio is equal to or less than 1.25 to 1.00), and (4) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions).
	Principal repayments of the new term loans, which are due quarterly, began in September 2013 and are equal to 1.0% of the original principal amount with any remaining balance payable on the final maturity date. Scheduled maturities with respect to the new term loans are as follows (in thousands):
	Year Ending December 31,	Scheduled New Term Loan Maturities
	2013 (remainder)	$	1,393
	2014	5,572
	2015	5,572
	2016	5,572
	2017	5,572
	Thereafter	532,114
	Total	$	555,795
	The amended credit agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to Jazz Pharmaceuticals plc and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The amended credit agreement contains a financial covenant that requires Jazz Pharmaceuticals plc and its restricted subsidiaries to maintain a maximum secured leverage ratio. We are currently in compliance with our financial covenants.
	The refinancing of the original term loans involved multiple lenders who were considered members of a loan syndicate. In determining whether the refinancing was to be accounted for as a debt extinguishment or modification, we considered whether the creditors remained the same or changed and whether the change in debt terms was substantial. The debt terms were considered substantially different if the present value of the cash flows of the new term loans was at least 10% different from the present value of the remaining cash flows of the original term loans, or the 10% Test. We performed a separate 10% Test for each individual creditor participating in the loan syndication. The loans of creditors who did not participate in the amended credit agreement were accounted for as a debt extinguishment. When there was a change in principal balance for individual creditors, in applying the 10% Test, we used the cash flows related to the lowest common principal balance, or the Net Method. Under the Net Method, any principal in excess of a creditor’s reinvested principal balance was treated as a new, separate debt issuance, and any decrease in principal was treated as a partial extinguishment of debt.
	For debt considered to be extinguished, the unamortized deferred financing costs and unamortized original issue discount associated with the extinguished debt were expensed. For debt considered to be modified, the unamortized deferred financing costs and unamortized original issue discount associated with the modified debt continue to be amortized, new creditor fees were capitalized and new third party fees were expensed. For new creditors, new creditor fees and new third party fees were capitalized. Deferred financing costs of $11.7 million and an original issue discount of $4.9 million were associated with modified and new debt and will be amortized to interest expense using the interest method over the life of the new term loans.
	As the borrowing capacity relating to each creditor under the new revolving credit facility was greater than that under the original revolving credit facility, unamortized deferred financing costs, new creditor fees and new third party fees, totaling $4.7 million, were associated with the new arrangement and were deferred and are being amortized to interest expense on a straight-line basis over the life of the facility. We did not borrow under the original revolving credit facility and, as of September 30, 2013, we had not borrowed under the new revolving credit facility.
	The refinancing resulted in a $3.7 million charge in the nine months ended September 30, 2013, which was comprised of $2.7 million related to the expensing of unamortized deferred financing costs and unamortized original issue discount associated with extinguished debt and $1.0 million related to new third party fees associated with modified debt.
	As of September 30, 2013, the interest rate on the new term loans was 3.5%. Interest expense associated with the new term loans is recorded using the interest method and includes non-cash interest related to the amortization of the debt discount and debt issuance costs. As of September 30, 2013, the effective interest rate on the new term loans was 4.3%. As of September 30, 2013, the current portion of the carrying amount of the new term loans was $5.6 million and the non-current portion was $545.6 million.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Indemnification
	In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.
	We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage and the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of September 30, 2013 and December 31, 2012. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.
	Lease and Other Commitments
	We have noncancelable operating leases for our office buildings and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force. Future minimum lease payments under our noncancelable operating leases at September 30, 2013 were as follows (in thousands):
	Year Ending December 31,	Lease
		Payments
	2013 (remainder)	$	2,391
	2014	9,496
	2015	8,832
	2016	5,404
	2017	2,606
	Thereafter	163
	Total	$	28,892
	In April 2013, we entered into a new operating lease agreement for additional office space in Palo Alto for a term of three years with an option to extend for one additional year.
	As of September 30, 2013, we had $68.1 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers.
	Legal Proceedings
	We are involved in several legal proceedings, including the following matters:
	Xyrem ANDA Matters: On October 18, 2010, we received a Paragraph IV Patent Certification notice, or Paragraph IV Certification, from Roxane Laboratories, Inc., or Roxane, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. Roxane’s Paragraph IV Certification alleged that all five patents then listed for Xyrem in the FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” or Orange Book, on the date of the Paragraph IV Certification are invalid, unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit against Roxane in response to Roxane’s Paragraph IV Certification in the United States District Court for the District of New Jersey, or the District Court. We are seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe our patents. Two additional method of use patents covering the distribution system for Xyrem were issued in December 2010 and February 2011, respectively, and were listed in the Orange Book, and we filed lawsuits against Roxane in February 2011 and again in May 2011 to include these additional patents in the litigation in response to Roxane’s Paragraph IV Certifications against each of these patents, and also to include another issued patent in the litigation which is not listed in the Orange Book. These additional lawsuits were subsequently consolidated with the action filed on November 22, 2010. On April 26, 2012, the District Court held a Markman hearing, a pretrial hearing following which the trial judge construes the claims of the patents at issue in a lawsuit, and the District Court issued a Markman order construing the claims of the patents then involved in the litigation in September 2012. Two additional patents, one covering a formulation of Xyrem and the other covering use of Xyrem for treatment of narcolepsy (Patent Nos. 8,263,650 and 8,324,275), or the ’650 patent and the ’275 patent, were issued in September 2012 and December 2012, respectively, and were listed in the Orange Book. In October 2012, we filed a new lawsuit in the District Court against Roxane in response to Roxane’s Paragraph IV Certification against the ’650 patent, or the ’650 case, and in December 2012, we filed a lawsuit in the District Court against Roxane alleging infringement of the ’275 patent, or the ’275 case. In April 2013, the District Court issued an order consolidating the three lawsuits and an order scheduling discovery and other deadlines for the consolidated case. Under the current scheduling order, fact discovery concerning the ’650 and ’275 patents will remain open until November 2013, and expert discovery involving all ten of the patents involved in the consolidated case will close in May 2014. Although no trial date for the consolidated case has been scheduled, based on the current scheduling order, we anticipate that trial in the consolidated case could occur as early as mid-2014. However, the actual timing of events in this litigation may be significantly earlier or later than contemplated by the scheduling order, and we cannot predict the timing or outcome of events in this litigation. In accordance with the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, as a result of our having filed a timely lawsuit against Roxane, FDA approval of Roxane’s ANDA had been stayed until April 18, 2013, which was 30 months after our October 18, 2010 receipt of Roxane’s Paragraph IV Certification, but that stay has expired. On September 30, 2013, we received a Paragraph IV Certification from Roxane alleging that a tenth patent listed in the Orange Book for Xyrem would not be infringed by Roxane’s proposed generic product.
	On December 10, 2012, we received a Paragraph IV Certification from Amneal Pharmaceuticals, LLC, or Amneal, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. Amneal’s Paragraph IV Certification alleged that seven patents listed for Xyrem in the Orange Book are not infringed by Amneal’s proposed generic product. Amneal’s Paragraph IV Certification further alleged that an eighth patent listed in the Orange Book for Xyrem is invalid. On December 13, 2012, we received a supplemental Paragraph IV Certification alleging that a ninth patent listed in the Orange Book for Xyrem is invalid. On January 18, 2013, we filed a lawsuit against Amneal in response to Amneal’s Paragraph IV Certifications in the District Court. On August 2, 2013 we received a Paragraph IV Certification alleging that a tenth patent listed in the Orange Book for Xyrem would not be infringed by Amneal’s proposed generic product. On September 12, 2013, we filed a lawsuit against Amneal alleging infringement of this patent as well as another issued patent which is not listed in the Orange Book. We are seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe our patents. In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Amneal, FDA approval of Amneal’s ANDA will be stayed until the earlier of (i) June 10, 2015, which is 30 months after our receipt of Amneal’s Paragraph IV Certification on December 10, 2012, or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed. We cannot predict the outcome of this matter.
	On May 18, 2012, we submitted a Citizen Petition to the FDA that addressed the legal and scientific bases for requiring in vivo bioequivalence studies for generic formulations of Xyrem. Among other actions requested of the FDA, this petition requested that the FDA (i) not accept for review, review, or approve any ANDA referencing Xyrem unless and until the FDA has published bioequivalence requirements in the Orange Book specifying whether in vitro bioequivalence studies, in vivo bioequivalence studies, or both, are required for such ANDAs and (ii) require in vivo bioequivalence studies for any sodium oxybate drug product for which approval is sought in an ANDA referencing Xyrem to the extent such drug product differs from Xyrem in manufacturing process, pH, excipients, impurities, degradants or contaminants.  On November 13, 2012, the FDA denied this Citizen Petition.  On July 10, 2012, we submitted a second Citizen Petition to the FDA that addressed the requirements for submission of any ANDA referencing Xyrem. This petition focused on our view that any ANDA referencing Xyrem must contain a proposed risk management system at the time it was or is filed in order to demonstrate, as required by law, that the new generic drug product would have the same labeling and conditions of use as Xyrem. Among other actions requested of the FDA, this petition asked the FDA to rescind the acceptance of any previously-accepted ANDA referencing Xyrem, including the Roxane ANDA, that did not contain a proposed risk management system at the time it was accepted for review.  On December 13, 2012, the FDA denied this Citizen Petition.  We continue to evaluate the FDA’s responses to both Citizen Petitions and potential further actions that we may take with respect to the issues raised in, and the FDA’s denials of, the Citizen Petitions. The FDA’s denial of the Citizen Petitions does not have a direct impact on the merits of our ongoing lawsuits with Roxane and Amneal.  However, we cannot predict the effect of the denial of either of our Citizen Petitions, or the FDA’s stated positions in its responses to the Citizen Petitions, on the timing of the potential introduction of a generic version of Xyrem.
	FazaClo ANDA Matters: Azur Pharma received Paragraph IV Certifications from three generics manufacturers, Barr Laboratories, Inc.; Novel Laboratories, Inc.; and Mylan Pharmaceuticals, Inc., indicating that ANDAs had been filed with the FDA requesting approval to market generic versions of FazaClo® (clozapine, USP) LD orally disintegrating clozapine tablets. Azur Pharma and CIMA Labs Inc., or CIMA, a subsidiary of Teva Pharmaceutical Industries Limited, or Teva, our licensor and the entity whose drug-delivery technology is incorporated into FazaClo LD, filed a lawsuit in response to each certification claiming infringement based on such certification: against Barr Laboratories, Inc. on August 21, 2008, against Novel Laboratories, Inc. on November 25, 2008, and against Mylan Pharmaceuticals, Inc. on July 23, 2010. Each case was filed in the United States District Court for the District of Delaware. On July 6, 2011, CIMA, Azur Pharma and Teva, which had acquired Barr Laboratories, Inc., entered into an agreement settling the patent litigation and Azur Pharma granted a sublicense to an affiliate of Teva of Azur Pharma’s rights to have manufactured, market and sell a generic version of both FazaClo LD and FazaClo HD, as well as an option for supply of authorized generic product. The sublicense for FazaClo LD commenced in July 2012, and the sublicense for FazaClo HD will commence in May 2015, or earlier upon the occurrence of certain events. Teva exercised its option for supply of an authorized generic product for FazaClo LD and launched the authorized generic product at the end of August 2012. The Novel Laboratories, Inc. and Mylan Pharmaceuticals, Inc. matters have been stayed pending reexamination of the patents in the lawsuits. In May 2013, a decision was issued by the U.S. Patent and Trademark Office, or the USPTO, in one of the two reexamination proceedings, which held certain claims patentable, and there was no appeal of this decision. The second reexamination proceeding is still ongoing. We cannot predict the outcome of the matters with Novel Laboratories, Inc. and Mylan Pharmaceuticals, Inc., the timing or outcome of the second reexamination proceeding, or when the stays will be lifted.
	Cutler Matter: On October 19, 2011, Dr. Neal Cutler, one of the original owners of FazaClo, filed a complaint against Azur Pharma and one of its subsidiaries, as well as Avanir Pharmaceuticals, Inc., or Avanir, in California Superior Court in the County of Los Angeles, or the Superior Court. The complaint alleges that Azur Pharma and its subsidiary breached certain contractual obligations. Azur Pharma acquired rights to FazaClo from Avanir in 2007. The complaint alleges that as part of the acquisition of FazaClo, Azur Pharma’s subsidiary agreed to assume certain contingent payment obligations to Dr. Cutler. The complaint further alleges that certain contingent payments are due because revenue thresholds have been achieved, entitling Dr. Cutler to either a $10.5 million or $25.0 million contingent payment, plus unspecified punitive damages and attorneys’ fees. On March 14, 2012, the Superior Court granted our petition to compel arbitration of the dispute in New York and stayed the Superior Court litigation. We submitted a complaint in arbitration alleging that Dr. Cutler’s suit had been improperly filed in Los Angeles and seeking a declaratory judgment that we have complied with all contractual obligations to Dr. Cutler. On July 25, 2012, the arbitrator dismissed the arbitration on the grounds that the parties’ dispute falls outside of the scope of the arbitration clause in the applicable contract. We have asked the Superior Court to vacate the arbitrator’s dismissal of the arbitration and appealed the Superior Court’s denial of our motion to the California Court of Appeal. In addition, on November 7, 2012, we filed challenges to the sufficiency of the complaint in the Superior Court, but the Superior Court case has been stayed pending the outcome of our appeal.  This matter, like all litigation, carries certain risks, and there can be no assurance of the outcome.
	From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Shareholders' Equity	'
	Shareholders’ Equity
	The following table presents a summary of ordinary shares issued or repurchased and related cash proceeds and payments (in thousands):
		Nine Months Ended					Nine Months Ended
		30-Sep-13					30-Sep-12
		Shares		Cash			Shares	Cash
	Proceeds from employee equity incentive and purchase plans and warrant exercises	1,448		$	23,577		2,943	$	20,994
	Share repurchases	(1,449	)	(102,397		)	—	—
	Employee withholding taxes related to share-based awards (1)	—		(5,303		)	—	(25,299		)
	Azur Merger	—		—			12,360	—
	Directors' deferred compensation plan	—		—			45	—
	Totals	(1	)	$	(84,123	)	15,348	$	(4,305	)
	____________________
	-1	During the nine months ended September 30, 2013, we paid $5.3 million of income tax withholdings on behalf of employees related to the net share settlement of vested RSUs. During the nine months ended September 30, 2012, we paid $25.3 million of income tax withholdings on behalf of certain employees of Jazz Pharmaceuticals, Inc. related to the net share settlement of exercised share options in connection with the Azur Merger. The income tax withholdings paid were recorded as a reduction to additional paid-in capital.
	Share Repurchase Program
	In May 2013, our board of directors authorized a share repurchase program pursuant to which we may repurchase a number of ordinary shares having an aggregate repurchase price of up to $200 million, exclusive of any brokerage commissions. The authorization became effective immediately and has no set expiration date. Under this authorization, we may repurchase our ordinary shares through open market purchases, privately negotiated purchases or a combination of these transactions. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the amended credit agreement, corporate and regulatory requirements and market conditions. Share repurchases may be suspended or discontinued at any time without prior notice. We initiated purchases under this program in May 2013. In the three months ended September 30, 2013, we spent a total of $48.8 million to repurchase 0.6 million of our ordinary shares at an average total purchase price, including commissions, of $80.91 per share. In the nine months ended September 30, 2013, we spent a total of $102.4 million to repurchase 1.4 million of our ordinary shares at an average total purchase price, including commissions, of $70.64 per share. All ordinary shares repurchased by the company were canceled. As of September 30, 2013, the remaining amount authorized under the share repurchase program was $97.6 million.
	Accumulated Other Comprehensive Income
	The components of accumulated other comprehensive income as of September 30, 2013 and December 31, 2012 were as follows (in thousands):
		Foreign			Total
		Currency			Accumulated
		Translation			Other
		Adjustments			Comprehensive
					Income
	Balance at December 31, 2012	$	31,046		$	31,046
	Other comprehensive income	13,576			13,576
	Balance at September 30, 2013	$	44,622		$	44,622
	During the nine months ended September 30, 2013, other comprehensive income reflects foreign currency translation adjustments which are primarily due to the strengthening of the Euro against the U.S. dollar.
	Additional Paid-in Capital
	In April 2013, the Irish High Court approved a $1.6 billion reduction of the share premium account of Jazz Pharmaceuticals plc to offset its accumulated deficit, with the resulting reserve to be treated as distributable reserves of our parent company. This transaction impacted our parent company balance sheet only and had no impact on our U.S. GAAP consolidated balance sheet.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-Based Compensation	'
	Share-Based Compensation
	Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Selling, general and administrative	$	9,354		$	5,330		$	25,898		$	11,967
	Research and development	1,931			681			4,453			1,718
	Cost of product sales	591			344			1,788			999
	Total share-based compensation expense, pre-tax	11,876			6,355			32,139			14,684
	Tax benefit from share-based compensation expense	(3,502		)	—			(9,850		)	—
	Total share-based compensation expense, net of tax	$	8,374		$	6,355		$	22,289		$	14,684
	Share Options
	The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Shares underlying options granted (in thousands)	105			1,157			1,277			2,077
	Grant date fair value	$	37.17		$	23.13		$	28.49		$	25.23
	Black-Scholes option pricing model assumption information:
	Volatility	57		%	64		%	59		%	64		%
	Expected term (years)	4.4			4.2			4.4			4.6
	Range of risk-free rates	1.0-1.4%			0.5-0.6%			0.5-1.4%			0.5-1.1%
	Expected dividend yield	—		%	—		%	—		%	—		%
	Restricted Stock Units
	The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	RSUs granted (in thousands)	46			550			568			1,002
	Grant date fair value	$	80.35		$	46.83		$	60.73		$	48.98
	The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares as of that date. The fair value of RSUs is recognized as expense ratably over the vesting period of four years.
	As of September 30, 2013, compensation cost not yet recognized related to unvested share options and RSUs was $58.3 million and $46.3 million, respectively, which is expected to be recognized over a weighted-average period of 2.7 years and 3.0 years, respectively.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	In March 2013, we entered into an underwriting agreement with an underwriter and certain selling shareholders, pursuant to which the selling shareholders sold to the underwriter 5.4 million of our ordinary shares, resulting in aggregate gross proceeds to the selling shareholders of approximately $314.4 million, before deducting underwriting discounts, commissions and other offering expenses. The selling shareholders included entities affiliated with certain members of our board of directors and one of our directors. We did not receive any proceeds from the sale of our ordinary shares by the selling shareholders in the offering and, consistent with our obligations under existing registration rights agreements with those shareholders, we paid expenses of approximately $0.5 million in connection with the offering.

Segment_and_Other_Information

Segment and Other Information	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment and Other Information	'
	Segment and Other Information
	Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker or, CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the development and commercialization of specialty pharmaceutical products. The following table presents a summary of total revenues (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013			2012				2013			2012
	Xyrem® (sodium oxybate) oral solution	$	153,664		$	102,615			$	404,932		$	265,149
	Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase®	44,078			31,652				130,754			37,660
	Prialt® (ziconotide) intrathecal infusion	11,046			5,413				20,726			20,491
	Psychiatry	10,679			21,032				40,093			58,518
	Other	10,919			13,418				35,097			16,767
	Product sales, net	230,386			174,130				631,602			398,585
	Royalties and contract revenues	1,774			1,385				5,047			3,691
	Total revenues	$	232,160		$	175,515			$	636,649		$	402,276
	The following table presents a summary of total revenues attributed to geographic sources (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013			2012				2013			2012
	United States	$	209,299		$	159,947			$	577,484		$	375,658
	Europe	19,332			12,164				46,769			21,252
	All other	3,529			3,404				12,396			5,366
	Total revenues	$	232,160		$	175,515			$	636,649		$	402,276
	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013		2012			2013			2012
	Express Scripts	66	%	58	%		63	%		66	%
	Accredo	16	%	14	%		17	%		7	%
	The following table presents total long-lived assets by location (in thousands):
		September 30,			December 31,
		2013			2012
	Ireland	$	4,057		$	2,437
	United States	7,394			4,451
	Other	609			393
	Total long-lived assets (1)	$	12,060		$	7,281
	_________________________
	-1	Long-lived assets consist of property and equipment.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	Restructuring
	Termination Benefits
	In June 2012, we initiated a restructuring plan to re-align certain support functions across the company following the Azur Merger and the EUSA Acquisition. In connection with this restructuring we incurred costs of severance for terminated employees as well as retention bonus costs for certain employees retained to assist with the transition process which was completed in June 2013. The one-time termination benefits were recorded over the remaining service period where employees were required to stay through their termination date to receive the benefits. We recorded costs related to these one-time termination benefits of $1.0 million in the nine months ended September 30, 2013 and $2.2 million in the nine months ended September 30, 2012, which are recorded within selling, general and administrative expenses in our condensed consolidated statements of income. To date, we have incurred one-time termination benefit costs under this plan of $3.8 million. We do not expect to incur any additional one-time termination benefit costs in connection with this plan.
	Facility Closure Costs
	In connection with our restructuring plan, we vacated our Langhorne, Pennsylvania facility in June 2013. We incurred facility closure costs of $0.4 million in the nine months ended September 30, 2013 for the remaining operating lease obligations related to this facility, net of estimated sublease rentals that could be reasonably obtained. Facility closure costs are recorded within selling, general and administrative expenses in our condensed consolidated statements of income. We do not expect to incur any additional facility closure costs in connection with this plan.
	The following table summarizes the amounts related to restructuring for the nine months ended September 30, 2013 (in thousands):
		Termination Benefits			Facility Closure Costs			Total
	Balance at December 31, 2012	$	1,227		$	—		$	1,227
	Costs incurred during the period	1,045			412			1,457
	Cash payments	(2,272		)	(104		)	(2,376		)
	Balance at September 30, 2013	$	—		$	308		$	308
	The balance at September 30, 2013 was included within accrued liabilities in our condensed consolidated balance sheet.

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations	'
	Discontinued Operations
	In 2012, we sold the women’s health business, a component of the acquired Azur Pharma business, to Meda Pharmaceuticals Inc. and Meda Pharma, Sàrl, or collectively, Meda. As part of the transaction, Meda purchased six women’s health products from us and offered positions to approximately 60 of our employees who directly supported the women’s health business.
	Net revenue and loss from discontinued operations were as follows (in thousands):
		Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
	Product sales, net	$	8,086		$	19,277
	Loss from discontinued operations (1)	$	(386	)	$	(6,908	)
	____________________
	-1	There was no income tax on the loss from discontinued operations.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Our income tax provision was $18.3 million and $59.6 million for the three and nine months ended September 30, 2013, respectively, compared to $12.9 million and $25.0 million for the same periods in 2012. Our effective tax rate from continuing operations was 19.6% and 27.0% for the three and nine months ended September 30, 2013, respectively, compared to 27.7% and 20.8% for the same periods in 2012. The decrease in the effective tax rate for the three months ended September 30, 2013 compared to the same period in 2012 was primarily due to estimated changes in the profit mix among the various tax jurisdictions in which we operate as well as higher taxes in 2012 related to acquisition restructuring. The increase in the effective tax rate for the nine months ended September 30, 2013 compared to the same period in 2012 was primarily due to a higher level of profits subject to U.S. federal and state income taxes in 2013, the release of a valuation allowance against substantially all of our U.S federal and state deferred tax assets in the fourth quarter of 2012 and a provision for income taxes on operations we acquired as part of the EUSA Acquisition. The effective tax rates for the 2013 periods were higher than the Irish statutory rate of 12.5% primarily due to income taxable at a rate higher than the Irish statutory rate, certain uncertain tax positions, current year losses in some jurisdictions for which no tax benefit is available, and various expenses not deductible for tax purposes, partially offset by benefits from certain originating income tax credits. Our income tax provision reflects our estimate of the effective tax rate expected to be applicable for the full year and we re-evaluate this estimate each quarter based on our forecasted tax expense for the full year. No provision for income tax in Ireland has been recognized on undistributed earnings of our foreign subsidiaries because we consider such earnings to be indefinitely reinvested.
	Our deferred tax assets are composed primarily of U.S. federal and state net operating loss carryforwards and tax credit carryforwards, foreign net operating loss carryforwards and other temporary differences. We maintain a valuation allowance against certain U.S. state and foreign deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction.
	We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have established a liability for certain tax benefits which we judge may not be sustained upon examination. We file income tax returns in Ireland, in the U.S. (both at the federal level and in various state jurisdictions) and in certain other foreign jurisdictions, all of which typically have three to four tax years open at any point in time. Because of our net operating loss carryforwards and tax credit carryforwards, substantially all of our tax years remain open to federal, state, and foreign tax examination. Certain of our subsidiaries are currently under examination by the U.S. Internal Revenue Service and by the French tax authorities.

The_Company_and_Summary_of_Sig1

The Company and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the annual consolidated financial statements and accompanying notes of Jazz Pharmaceuticals plc included in its Annual Report on Form 10-K for the year ended December 31, 2012. The results of operations of the acquired Azur Pharma and EUSA Pharma businesses, along with the estimated fair values of the assets acquired and liabilities assumed in each transaction, have been included in our condensed consolidated financial statements since the effective dates of the Azur Merger and the EUSA Acquisition, respectively.
	In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013, for any other interim period or for any future period.
	Certain prior period amounts presented in the accompanying footnotes have been reclassified to conform to current period presentation, as described in Note 2.
	These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our wholly-owned subsidiaries and intercompany transactions and balances have been eliminated.
Significant Risks and Uncertainties	'
	Significant Risks and Uncertainties
	Our financial results are significantly influenced by sales of Xyrem® (sodium oxybate) oral solution. Maintaining or increasing sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition, changed or increased regulatory restrictions, and continued acceptance of Xyrem as safe and effective by physicians and patients. Two abbreviated new drug applications, or ANDAs, have been filed with the United States Food and Drug Administration, or FDA, by third parties seeking to market generic versions of Xyrem. We have sued both third parties for infringement of our patents, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	We are continuing our efforts on various regulatory matters, including working with the FDA on updated documents that we have submitted to the FDA on our risk management and controlled distribution system for Xyrem, which we refer to as the Xyrem Risk Management Program, and potential modifications to this program. We are engaged in ongoing communications with the FDA with respect to our risk evaluation and mitigation strategies, or REMS, documents for Xyrem, but we have not reached agreement on certain significant terms. For example, we disagree with the FDA’s current position that, as part of the current REMS process, the Xyrem deemed REMS should be modified to enable the distribution of Xyrem through more than one pharmacy. We expect that final REMS documents for Xyrem will include modifications to, and/or requirements that are not currently implemented in, the Xyrem Risk Management Program. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors to enter the market and/or negatively affect sales of Xyrem. We cannot predict whether, or on what terms, we will reach agreement with FDA on final REMS documents for Xyrem, whether we will initiate dispute resolution or other proceedings with FDA prior to finalizing the REMS documents, or, if any such proceedings are initiated, the outcome or timing thereof.
	In addition, the FDA is seeking to schedule an initial meeting with us and ANDA applicants to facilitate the development of a single shared system REMS for Xyrem (sodium oxybate). Also, we may face pressure to license or share our Xyrem Risk Management Program, which is the subject of multiple issued patents, or elements of it, with generic competitors. We cannot predict the outcome or impact on our business of any discussions with the FDA and/or any ANDA applicant with respect to the potential creation of a single shared system REMS for Xyrem, any future action that may be taken by a third party to seek to license or share our REMS, or the FDA’s response to a certification that a third party has been unable to obtain a license.
	Our financial results are increasingly influenced by sales of our second largest product, Erwinaze® (asparaginase Erwinia chrysanthemi), which have continued to grow. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available through ongoing research and development activities. However, our ability to successfully and sustainably grow sales of Erwinaze is subject to a number of risks and uncertainties, including assuring sufficient supply of Erwinaze on a timely basis, the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli-derived asparaginase within that population, and our need to apply for and receive marketing authorizations in certain additional countries so we can launch promotional efforts in those countries. We maintain very limited inventory of Erwinaze and, in 2013, our supply of Erwinaze was nearly completely absorbed by demand for the product. While we have been able to resolve potential supply shortages and meet product demand to date, if our continued efforts to avoid supply shortages are not successful, we could experience Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product.
	In addition to risks related specifically to Xyrem and Erwinaze, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly because we maintain limited inventories of certain products, including products for which our supply demands are growing, and we are dependent on single source suppliers to continue to meet our ongoing commercial needs; the need to obtain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to health care cost containment and other austerity measures in the United States and worldwide; the ongoing regulation and oversight by the FDA, the U.S. Drug Enforcement Administration, or DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals; the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance of our products by patients, physicians and payors; and the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval. Other risks and uncertainties related to our ability to execute on our strategy include: our ability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations.
Concentrations of Risk	'
	Concentrations of Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist of cash equivalents and marketable securities. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.
	We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to hospitals, pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of September 30, 2013, five customers accounted for 88% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, which accounted for 73% of gross accounts receivable, and Accredo Health Group, Inc., or Accredo, which accounted for 7% of gross accounts receivable. As of December 31, 2012, five customers accounted for 78% of gross accounts receivable, including Express Scripts, which accounted for 51% of gross accounts receivable, and Accredo, which accounted for 11% of gross accounts receivable.
	We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
Net Income per Ordinary Share	'
	Net Income per Ordinary Share
	Basic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Numerator:
	Income from continuing operations	$	75,409		$	33,595		$	161,019	$	94,943
	Loss from discontinued operations	—			(386		)	—		(6,908		)
	Net income	$	75,409		$	33,209		$	161,019	$	88,035
	Denominator:
	Weighted-average ordinary shares - basic	58,217			57,703			58,437		56,198
	Dilutive effect of employee equity incentive and purchase plans	1,852			1,404			1,587		1,557
	Dilutive effect of warrants	1,450			1,776			1,508		2,091
	Weighted-average ordinary shares - diluted	61,519			60,883			61,532		59,846
	Basic income (loss) per ordinary share:
	Income from continuing operations	$	1.3		$	0.59		$	2.76	$	1.69
	Loss from discontinued operations	—			(0.01		)	—		(0.12		)
	Net income	$	1.3		$	0.58		$	2.76	$	1.57
	Diluted income (loss) per ordinary share:
	Income from continuing operations	$	1.23		$	0.56		$	2.62	$	1.59
	Loss from discontinued operations	—			(0.01		)	—		(0.12		)
	Net income	$	1.23		$	0.55		$	2.62	$	1.47
	Potentially dilutive ordinary shares from employee equity plans and warrants are determined by applying the treasury stock method to the assumed exercise of warrants and share options, the assumed vesting of outstanding restricted stock units, or RSUs, and the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP. The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013		2012			2013		2012
	Options to purchase ordinary shares and RSUs	1,028		1,785			2,074		1,314

The_Company_and_Summary_of_Sig2

The Company and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basic and Diluted Net Income per Ordinary Share Computation	'
	Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Numerator:
	Income from continuing operations	$	75,409		$	33,595		$	161,019	$	94,943
	Loss from discontinued operations	—			(386		)	—		(6,908		)
	Net income	$	75,409		$	33,209		$	161,019	$	88,035
	Denominator:
	Weighted-average ordinary shares - basic	58,217			57,703			58,437		56,198
	Dilutive effect of employee equity incentive and purchase plans	1,852			1,404			1,587		1,557
	Dilutive effect of warrants	1,450			1,776			1,508		2,091
	Weighted-average ordinary shares - diluted	61,519			60,883			61,532		59,846
	Basic income (loss) per ordinary share:
	Income from continuing operations	$	1.3		$	0.59		$	2.76	$	1.69
	Loss from discontinued operations	—			(0.01		)	—		(0.12		)
	Net income	$	1.3		$	0.58		$	2.76	$	1.57
	Diluted income (loss) per ordinary share:
	Income from continuing operations	$	1.23		$	0.56		$	2.62	$	1.59
	Loss from discontinued operations	—			(0.01		)	—		(0.12		)
	Net income	$	1.23		$	0.55		$	2.62	$	1.47
Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share	'
	The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013		2012			2013		2012
	Options to purchase ordinary shares and RSUs	1,028		1,785			2,074		1,314

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Components of Inventories	'
	Inventories consisted of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Raw materials	$	4,474	$	4,979
	Work in process	6,523		5,410
	Finished goods	13,871		16,136
	Total inventories	$	24,868	$	26,525

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Cash Cash Equivalents and Marketable Securities	'
	Cash and cash equivalents consisted of the following (in thousands):
		30-Sep-13
		Amortized		Gross		Gross		Estimated		Cash and		Marketable
		Cost		Unrealized		Unrealized		Fair Value		Cash		Securities
				Gains		Losses				Equivalents
	Cash	$	295,970	$	—	$	—	$	295,970	$	295,970	$	—
	Time deposits	292,492		—		—		292,492		292,492		—
	Totals	$	588,462	$	—	$	—	$	588,462	$	588,462	$	—
		31-Dec-12
		Amortized		Gross		Gross		Estimated		Cash and		Marketable
		Cost		Unrealized		Unrealized		Fair Value		Cash		Securities
				Gains		Losses				Equivalents
	Cash	$	343,548	$	—	$	—	$	343,548	$	343,548	$	—
	Money market funds	43,648		—		—		43,648		43,648		—
	Totals	$	387,196	$	—	$	—	$	387,196	$	387,196	$	—
Available-for-Sale Securities and Other Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes, by major security type, our available-for-sale securities and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
		30-Sep-13								31-Dec-12
		Quoted		Significant Other		Significant		Total		Quoted		Significant		Total
		Prices in		Observable		Unobservable		Estimated		Prices in		Unobservable		Estimated
		Active		Inputs		Inputs		Fair Value		Active		Inputs		Fair Value
		Markets for		(Level 2)		(Level 3)				Markets for		(Level 3)
		Identical								Identical
		Assets								Assets
		(Level 1)								(Level 1)
	Assets:
	Available-for-sale securities
	Time deposits	$	—	$	292,492	$	—	$	292,492	$	—	$	—	$	—
	Money market funds	—		—		—		—		43,648		—		43,648
	Totals	$	—	$	292,492	$	—	$	292,492	$	43,648	$	—	$	43,648
	Liabilities:
	Contingent consideration	$	—	$	—	$	47,700	$	47,700	$	—	$	34,800	$	34,800
Change in Fair Value of Contingent Consideration	'
	The change in fair value of the contingent consideration payable was estimated as follows (in thousands):
		Level 3
	Balance at December 31, 2012	$	34,800
	Fair value adjustment recorded within selling, general and administrative expenses	12,900
	Balance at September 30, 2013	$	47,700

Certain_Balance_Sheet_Items_Ta

Certain Balance Sheet Items (Tables)	9 Months Ended
	Sep. 30, 2013
Certain Balance Sheet Items [Abstract]	'
Property and Equipment	'
	Property and equipment consisted of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Computer software	$	7,670		$	4,292
	Computer equipment	5,059			3,687
	Leasehold improvements	4,303			3,899
	Construction-in-progress	2,638			1,135
	Furniture and fixtures	1,966			1,953
	Machinery and equipment	186			94
	Subtotal	21,822			15,060
	Less accumulated depreciation and amortization	(9,762		)	(7,779		)
	Property and equipment, net	$	12,060		$	7,281
Accrued Liabilities	'
	Accrued liabilities consisted of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Rebates and other sales deductions	$	37,125		$	29,235
	Employee compensation and benefits	26,263			24,900
	Sales returns reserve	21,756			26,385
	Royalties	3,139			3,271
	Professional fees	1,944			2,163
	Other	16,163			18,712
	Total accrued liabilities	$	106,390		$	104,666

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Gross Carrying Amount of Goodwill	'
	The gross carrying amount of goodwill was as follows (in thousands):
	Balance at December 31, 2012	$	442,600
	Foreign exchange	4,223
	Balance at September 30, 2013	$	446,823
Gross Carrying Amounts and Net Book Values of Intangible Assets	'
	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):
		September 30, 2013									December 31, 2012
		Remaining		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Weighted-		Carrying		Amortization			Value		Carrying		Amortization			Value
		Average Useful		Amount							Amount
		Life
		(In years)
	Acquired developed technologies	11.7		$	946,595	$	(157,423	)	$	789,172	$	930,834	$	(97,578	)	$	833,256
	Trademarks	1.3		2,600		(2,259		)	341		2,600		(2,054		)	546
	Total finite-lived intangible assets			949,195		(159,682		)	789,513		933,434		(99,632		)	833,802
	Acquired IPR&D assets			34,211		—			34,211		36,150		—			36,150
	Total intangible assets			$	983,406	$	(159,682	)	$	823,724	$	969,584	$	(99,632	)	$	869,952
Estimated Future Amortization Costs	'
	Based on finite-lived intangible assets recorded as of September 30, 2013, and assuming the underlying assets will not be impaired in the future and that we will not change the expected lives of the assets, future amortization costs were estimated as follows (in thousands):
	Year Ending December 31,	Estimated
		Amortization
		Expense
	2013 (remainder)	$	19,872
	2014	79,284
	2015	73,238
	2016	68,908
	2017	68,816
	Thereafter	479,395
	Total	$	789,513

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Maturities of New Term Loans	'
	Scheduled maturities with respect to the new term loans are as follows (in thousands):
	Year Ending December 31,	Scheduled New Term Loan Maturities
	2013 (remainder)	$	1,393
	2014	5,572
	2015	5,572
	2016	5,572
	2017	5,572
	Thereafter	532,114
	Total	$	555,795

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments under Noncancelable Operating Leases	'
	Future minimum lease payments under our noncancelable operating leases at September 30, 2013 were as follows (in thousands):
	Year Ending December 31,	Lease
		Payments
	2013 (remainder)	$	2,391
	2014	9,496
	2015	8,832
	2016	5,404
	2017	2,606
	Thereafter	163
	Total	$	28,892

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Ordinary Shares Issued and Proceeds Received	'
	The following table presents a summary of ordinary shares issued or repurchased and related cash proceeds and payments (in thousands):
		Nine Months Ended					Nine Months Ended
		30-Sep-13					30-Sep-12
		Shares		Cash			Shares	Cash
	Proceeds from employee equity incentive and purchase plans and warrant exercises	1,448		$	23,577		2,943	$	20,994
	Share repurchases	(1,449	)	(102,397		)	—	—
	Employee withholding taxes related to share-based awards (1)	—		(5,303		)	—	(25,299		)
	Azur Merger	—		—			12,360	—
	Directors' deferred compensation plan	—		—			45	—
	Totals	(1	)	$	(84,123	)	15,348	$	(4,305	)
	____________________
	-1	During the nine months ended September 30, 2013, we paid $5.3 million of income tax withholdings on behalf of employees related to the net share settlement of vested RSUs. During the nine months ended September 30, 2012, we paid $25.3 million of income tax withholdings on behalf of certain employees of Jazz Pharmaceuticals, Inc. related to the net share settlement of exercised share options in connection with the Azur Merger. The income tax withholdings paid were recorded as a reduction to additional paid-in capital.
Component of Accumulated Other Comprehensive Loss	'
	The components of accumulated other comprehensive income as of September 30, 2013 and December 31, 2012 were as follows (in thousands):
		Foreign			Total
		Currency			Accumulated
		Translation			Other
		Adjustments			Comprehensive
					Income
	Balance at December 31, 2012	$	31,046		$	31,046
	Other comprehensive income	13,576			13,576
	Balance at September 30, 2013	$	44,622		$	44,622

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-Based Compensation Expense	'
	Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Selling, general and administrative	$	9,354		$	5,330		$	25,898		$	11,967
	Research and development	1,931			681			4,453			1,718
	Cost of product sales	591			344			1,788			999
	Total share-based compensation expense, pre-tax	11,876			6,355			32,139			14,684
	Tax benefit from share-based compensation expense	(3,502		)	—			(9,850		)	—
	Total share-based compensation expense, net of tax	$	8,374		$	6,355		$	22,289		$	14,684
Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model which was Used to Estimate Grant Date Fair Value per Share	'
	The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Shares underlying options granted (in thousands)	105			1,157			1,277			2,077
	Grant date fair value	$	37.17		$	23.13		$	28.49		$	25.23
	Black-Scholes option pricing model assumption information:
	Volatility	57		%	64		%	59		%	64		%
	Expected term (years)	4.4			4.2			4.4			4.6
	Range of risk-free rates	1.0-1.4%			0.5-0.6%			0.5-1.4%			0.5-1.1%
	Expected dividend yield	—		%	—		%	—		%	—		%
Schedule of Restricted Stock Unit activity	'
	The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	RSUs granted (in thousands)	46			550			568			1,002
	Grant date fair value	$	80.35		$	46.83		$	60.73		$	48.98

Segment_and_Other_Information_

Segment and Other Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Summary of Total Revenues	'
	The following table presents a summary of total revenues (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013			2012				2013			2012
	Xyrem® (sodium oxybate) oral solution	$	153,664		$	102,615			$	404,932		$	265,149
	Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase®	44,078			31,652				130,754			37,660
	Prialt® (ziconotide) intrathecal infusion	11,046			5,413				20,726			20,491
	Psychiatry	10,679			21,032				40,093			58,518
	Other	10,919			13,418				35,097			16,767
	Product sales, net	230,386			174,130				631,602			398,585
	Royalties and contract revenues	1,774			1,385				5,047			3,691
	Total revenues	$	232,160		$	175,515			$	636,649		$	402,276
Summary of Total Revenues Attributed to Geographic Sources	'
	The following table presents a summary of total revenues attributed to geographic sources (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013			2012				2013			2012
	United States	$	209,299		$	159,947			$	577,484		$	375,658
	Europe	19,332			12,164				46,769			21,252
	All other	3,529			3,404				12,396			5,366
	Total revenues	$	232,160		$	175,515			$	636,649		$	402,276
Summary of Revenues from Customers Representing More Than 10% of Total Revenues	'
	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013		2012			2013			2012
	Express Scripts	66	%	58	%		63	%		66	%
	Accredo	16	%	14	%		17	%		7	%
Total Long-Lived Assets by Location	'
	The following table presents total long-lived assets by location (in thousands):
		September 30,			December 31,
		2013			2012
	Ireland	$	4,057		$	2,437
	United States	7,394			4,451
	Other	609			393
	Total long-lived assets (1)	$	12,060		$	7,281
	_________________________
	-1	Long-lived assets consist of property and equipment.

Restructuring_Tables

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Costs	'
	The following table summarizes the amounts related to restructuring for the nine months ended September 30, 2013 (in thousands):
		Termination Benefits			Facility Closure Costs			Total
	Balance at December 31, 2012	$	1,227		$	—		$	1,227
	Costs incurred during the period	1,045			412			1,457
	Cash payments	(2,272		)	(104		)	(2,376		)
	Balance at September 30, 2013	$	—		$	308		$	308

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Schedule of disposal groups	'
	Net revenue and loss from discontinued operations were as follows (in thousands):
		Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
	Product sales, net	$	8,086		$	19,277
	Loss from discontinued operations (1)	$	(386	)	$	(6,908	)
	____________________
	-1	There was no income tax on the loss from discontinued operations.

The_Company_and_Summary_of_Sig3

The Company and Summary of Significant Accounting Policies - Additional Information (Detail)	Sep. 30, 2013	Dec. 31, 2012
	Customer	Customer
Summary Of Significant Accounting Policies [Line Items]	'	'
Number of customers with significant accounts receivable	5	5
Percentage of gross accounts receivable	88.00%	78.00%
Express Scripts [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Percentage of gross accounts receivable	73.00%	51.00%
Accredo Health Group, Inc. [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Percentage of gross accounts receivable	7.00%	11.00%

Basic_and_Diluted_Net_Income_L

Basic and Diluted Net Income (Loss) per Common Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Income from continuing operations	$75,409	$33,595	$161,019	$94,943
Loss from discontinued operations	0	-386	0	-6,908
Net income	$75,409	$33,209	$161,019	$88,035
Denominator:	'	'	'	'
Weighted-average ordinary shares - basic (in shares)	58,217	57,703	58,437	56,198
Dilutive effect of employee equity incentive and purchase plans (in shares)	1,852	1,404	1,587	1,557
Dilutive effect of warrants (in shares)	1,450	1,776	1,508	2,091
Weighted-average ordinary shares - diluted (in shares)	61,519	60,883	61,532	59,846
Basic income (loss) per ordinary share:	'	'	'	'
Income from continuing operations (in dollars per share)	$1.30	$0.59	$2.76	$1.69
Loss from discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.12)
Net income (in dollars per share)	$1.30	$0.58	$2.76	$1.57
Diluted income (loss) per ordinary share:	'	'	'	'
Income from continuing operations (in dollars per share)	$1.23	$0.56	$2.62	$1.59
Loss from discontinued operations (in dollars per share)	$0	($0.01)	$0	($0.12)
Net income (in dollars per share)	$1.23	$0.55	$2.62	$1.47

WeightedAverage_Ordinary_Share

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accounting Policies [Abstract]	'	'	'	'
Options to purchase ordinary shares and RSUs	1,028	1,785	2,074	1,314

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$4,474	$4,979
Work in process	6,523	5,410
Finished goods	13,871	16,136
Total inventories	$24,868	$26,525

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Schedule of Inventory [Line Items]	'	'
Inventory reclassified from raw materials to work in process	'	$4.20
Fair Value Adjustment to Inventory [Member]	'	'
Schedule of Inventory [Line Items]	'	'
Inventory, Step-up value	$0.80	$4

Summary_of_Cash_Cash_Equivalen

Summary of Cash, Cash Equivalents and Marketable Securities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Cash, cash equivalents and marketable securities [Line Items]	'	'	'	'
Amortized Cost	$588,462	$387,196	'	'
Estimated Fair Value	588,462	387,196	'	'
Cash and cash equivalents	588,462	387,196	189,793	82,076
Cash [Member]	'	'	'	'
Cash, cash equivalents and marketable securities [Line Items]	'	'	'	'
Amortized Cost	295,970	343,548	'	'
Estimated Fair Value	295,970	343,548	'	'
Cash and cash equivalents	295,970	343,548	'	'
Money market funds [Member]	'	'	'	'
Cash, cash equivalents and marketable securities [Line Items]	'	'	'	'
Amortized Cost	'	43,648	'	'
Estimated Fair Value	'	43,648	'	'
Cash and cash equivalents	'	43,648	'	'
Time deposits [Member]	'	'	'	'
Cash, cash equivalents and marketable securities [Line Items]	'	'	'	'
Amortized Cost	292,492	'	'	'
Estimated Fair Value	292,492	'	'	'
Cash and cash equivalents	$292,492	'	'	'

Fair_Value_Additional_Informat

Fair Value - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value Measurements [Line Items]	'	'
Transfers of assets from Level 1 to Level 2	$0	$0
Term Loans [Member]	'	'
Fair Value Measurements [Line Items]	'	'
Principal amount of term loan	555,800,000	'
Fair value of term loan	555,100,000	'
Carrying value of term loan	551,100,000	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value Measurements [Line Items]	'	'
Target sales of Erwinaze in 2013	124,500,000	'
Cash Distribution [Member] | Minimum [Member]	'	'
Fair Value Measurements [Line Items]	'	'
Contingent consideration	0	'
Cash Distribution [Member] | Maximum [Member]	'	'
Fair Value Measurements [Line Items]	'	'
Contingent consideration	$50,000,000	'

Fair_Value_Measurement_Availab

Fair Value Measurement Available-For-Sale Investments Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Amortized Cost	$588,462	$387,196
Available-for-sale securities measured at fair value on recurring basis	588,462	387,196
Money market funds [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Amortized Cost	'	43,648
Available-for-sale securities measured at fair value on recurring basis	'	43,648
Time deposits [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Amortized Cost	292,492	'
Available-for-sale securities measured at fair value on recurring basis	292,492	'
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Amortized Cost	0	43,648
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | Money market funds [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Amortized Cost	0	43,648
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Amortized Cost	292,492	'
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Time deposits [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Amortized Cost	292,492	'
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Contingent consideration [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Contingent consideration	47,700	34,800
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Available-for-sale securities measured at fair value on recurring basis	292,492	43,648
Contingent consideration	47,700	34,800
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Measurements, Recurring [Member] | Money market funds [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Available-for-sale securities measured at fair value on recurring basis	0	43,648
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Measurements, Recurring [Member] | Time deposits [Member]	'	'
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]	'	'
Available-for-sale securities measured at fair value on recurring basis	$292,492	'

Fair_Value_Measurement_Level_3

Fair Value Measurement Level 3 Input Roll Forward (Details) (Contingent consideration [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Contingent consideration [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Beginning balance	$34,800
Fair value adjustment recorded within selling, general and administrative expenses	12,900
Ending Balance	$47,700

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Certain Balance Sheet Items [Abstract]	'	'
Computer software	$7,670	$4,292
Computer equipment	5,059	3,687
Leasehold improvements	4,303	3,899
Construction-in-progress	2,638	1,135
Furniture and fixtures	1,966	1,953
Machinery and equipment	186	94
Subtotal	21,822	15,060
Less accumulated depreciation and amortization	-9,762	-7,779
Property and equipment, net	$12,060	$7,281

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Certain Balance Sheet Items [Abstract]	'	'
Rebates and other sales deductions	$37,125	$29,235
Employee compensation and benefits	26,263	24,900
Sales returns reserve	21,756	26,385
Royalties	3,139	3,271
Professional fees	1,944	2,163
Other	16,163	18,712
Total accrued liabilities	$106,390	$104,666

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Goodwill [Roll Forward]	'
Goodwill, beginning of period	$442,600
Foreign exchange	4,223
Goodwill, end of period	$446,823

Gross_Carrying_Amounts_and_Net

Gross Carrying Amounts and Net Book Values of Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount - Finite-Lived Intangible Assets	$949,195	$933,434
Accumulated Amortization - Finite-Lived Intangible Assets	-159,682	-99,632
Net Book Value - Finite-Lived Intangible Assets	789,513	833,802
Gross Carrying Amount - Total Intangible Assets	983,406	969,584
Net Book Value - Total Intangible Assets	823,724	869,952
Acquired IPR&D assets [Member]	'	'
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]	'	'
In-process research and development	34,211	36,150
Acquired developed technologies [Member]	'	'
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]	'	'
Remaining Weighted- Average Useful Life (In years)	'11 years 8 months 24 days	'
Gross Carrying Amount - Finite-Lived Intangible Assets	946,595	930,834
Accumulated Amortization - Finite-Lived Intangible Assets	-157,423	-97,578
Net Book Value - Finite-Lived Intangible Assets	789,172	833,256
Trademarks [Member]	'	'
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]	'	'
Remaining Weighted- Average Useful Life (In years)	'1 year 3 months	'
Gross Carrying Amount - Finite-Lived Intangible Assets	2,600	2,600
Accumulated Amortization - Finite-Lived Intangible Assets	-2,259	-2,054
Net Book Value - Finite-Lived Intangible Assets	$341	$546

Estimated_Future_Amortization_

Estimated Future Amortization Costs (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Estimated Amortization Expense	'	'
2013 (remainder)	$19,872	'
2014	79,284	'
2015	73,238	'
2016	68,908	'
2017	68,816	'
Thereafter	479,395	'
Net Book Value - Finite-Lived Intangible Assets	$789,513	$833,802

Debt_Details

Debt (Details) (USD $)

9 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jun. 13, 2013

Jun. 13, 2013

Jun. 13, 2013

Jun. 12, 2012

Jun. 13, 2013

Sep. 30, 2013

Jun. 13, 2013

Jun. 13, 2013

Jun. 13, 2013

Jun. 13, 2013

Jun. 13, 2013

Jun. 13, 2013

Jun. 13, 2013

Jun. 13, 2013

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2012 Credit Agreement [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Rate One [Member]

Rate One [Member]

Rate Two [Member]

Rate Two [Member]

Rate Option Three [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2012 Credit Agreement [Member]

2013 Credit Agreement [Member]

Term Loan [Member]

2013 Credit Agreement [Member]

Term Loan [Member]

Term Loan [Member]

LIBOR [Member]

Prime Rate [Member]

LIBOR [Member]

Prime Rate [Member]

Revolving Credit Facility [Member]

2013 Credit Agreement [Member]

Revolving Credit Facility [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current portion of long-term debt

$5,572,000

'

$29,688,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of term loan

'

'

'

'

'

'

'

557,188,000

'

'

'

'

'

'

'

'

'

Credit facility borrowing capacity

'

'

'

200,000,000

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

Repayment of long-term debt

464,517,000

5,938,000

'

'

'

'

'

'

'

'

'

457,200,000

'

'

'

'

'

Debt maturity date

'

'

'

12-Jun-17

'

'

'

12-Jun-18

'

'

'

'

'

'

'

'

'

Basis spread on variable rate

'

'

'

'

2.50%

1.50%

'

'

'

2.75%

1.75%

'

'

'

'

'

'

Term loan interest rate minimum percentage

'

'

'

'

'

'

'

'

'

0.75%

1.75%

'

'

'

'

'

'

Interest rate reduction basis points

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

0.50%

'

'

Commitment fee on credit facility, percentage

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

0.50%

'

'

Repricing premium before 12/13/13

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

Mandatory prepayments as percentage of excess cash flow beginning in 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

25.00%

0.00%

Percentage of principal amount for repayment

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

Long-term debt, less current portion

$545,564,000

'

$427,073,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Schedule_of_Maturities_Details

Schedule of Maturities (Details) (Term Loan [Member], 2013 Credit Agreement [Member], USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Term Loan [Member] | 2013 Credit Agreement [Member]	'
Debt Instrument [Line Items]	'
2013 (remainder)	$1,393
2014	5,572
2015	5,572
2016	5,572
2017	5,572
Thereafter	532,114
Long-term Debt	$555,795

LongTerm_Debt_Extinguishment_a

Long-Term Debt Extinguishment and Modification of Debt (Details) (USD $)	3 Months Ended		9 Months Ended			0 Months Ended	9 Months Ended	0 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Jun. 13, 2013	Sep. 30, 2013	Jun. 13, 2013
						Term Loan [Member]	Term Loan [Member]	Revolving Credit Facility [Member]
							2013 Credit Agreement [Member]	2013 Credit Agreement [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Debt financing costs	'	'	$1,049,000	'	'	'	'	'
Original issue discount	'	'	'	'	'	4,934,000	'	'
Unamortized deferred financing costs and new lender fees	'	'	'	'	'	11,749,000	'	4,718,000
Expense cost of unamortized deferred finance costs and unamortized issue discount associated with extinguished debt	'	'	2,700,000	'	'	'	'	'
Loss on extinguishment and modification of debt	0	0	3,749,000	0	'	'	'	'
Term loan interest rate	'	'	'	'	'	'	3.50%	'
Term loan effective interest rate	'	'	'	'	'	'	4.30%	'
Current portion of long-term debt	5,572,000	'	5,572,000	'	29,688,000	'	'	'
Long-term debt, less current portion	$545,564,000	'	$545,564,000	'	$427,073,000	'	'	'
Term loan, frequency of periodic payment	'	'	'	'	'	'	'Quarterly	'

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments under Noncancelable Operating Leases (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Lease Payments	'
2013 (remainder)	$2,391
2014	9,496
2015	8,832
2016	5,404
2017	2,606
Thereafter	163
Total	$28,892

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	Sep. 30, 2013	Oct. 19, 2011	Apr. 30, 2013
		Pending Litigation [Member]	Lease Agreements [Member]
			Palo Alto [Member]
Commitments and Contingencies Disclosure [Line Items]	'	'	'
Operating Lease, Renewed Term	'	'	'3 years
Noncancelable purchase commitments, due within one year	$68,100,000	'	'
Loss Contingency, Range of Possible Loss, Minimum	'	10,500,000	'
Loss Contingency, Range of Possible Loss, Maximum	'	$25,000,000	'

Ordinary_Shares_Issued_Repurch

Ordinary Shares Issued, Repurchased and Related Cash Proceeds and Payments (Detail) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended
	31-May-13	Sep. 30, 2013	Sep. 30, 2013		Sep. 30, 2012
Stock Activity [Line Items]	'	'	'		'
Share repurchases	'	'	($102,397,000)		$0
Payment of employee withholding taxes related to share-based awards	'	'	-5,303,000		-25,299,000
Ordinary Shares [Member]	'	'	'		'
Stock Activity [Line Items]	'	'	'		'
Proceeds from employee equity incentive and purchase plans and warrant exercises, shares	'	'	1,448,000		2,943,000
Shares repurchased, shares	'	-603,000	-1,449,000		0
Merger with Azur Pharma, shares issued	'	'	0		12,360,000
Directors deferred compensation plan, shares issued	'	'	0		45,000
Totals, shares issued	'	'	-1,000		15,348,000
Proceeds from employee equity incentive and purchase plans and warrant exercises	'	'	23,577,000		20,994,000
Share repurchases	'	-48,819,000	-102,397,000		'
Payment of employee withholding taxes related to share-based awards	'	'	-5,303,000	[1]	-25,299,000	[1]
Totals, cash proceeds and payments	'	'	-84,123,000		-4,305,000
Treasury Stock Acquired, Average Cost Per Share	'	$80.91	$70.64		'
Total amount authorized for repurchase of shares under share repurchase program	200,000,000	'	'		'
Remaining amount authorized for repurchase of shares	'	'	$97,633,000		'
[1]	During the nine months ended September 30, 2013, we paid $5.3 million of income tax withholdings on behalf of employees related to the net share settlement of vested RSUs. During the nine months ended September 30, 2012, we paid $25.3 million of income tax withholdings on behalf of certain employees of Jazz Pharmaceuticals, Inc. related to the net share settlement of exercised share options in connection with the Azur Merger. The income tax withholdings paid were recorded as a reduction to additional paid-in capital.

Component_of_Accumulated_Other

Component of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Balance at December 31, 2012	'	'	$31,046	'
Other comprehensive income (loss)	25,402	14,248	13,576	13,891
Balance at September 30, 2013	44,622	'	44,622	'
Foreign Currency Translation Adjustments [Member]	'	'	'	'
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Balance at December 31, 2012	'	'	31,046	'
Other comprehensive income (loss)	'	'	13,576	'
Balance at September 30, 2013	$44,622	'	$44,622	'

Shareholders_Equity_Additional

Shareholders' Equity Additional Paid In Capital (Details) (USD $)	Apr. 30, 2013
In Billions, unless otherwise specified
Stockholders' Equity Note [Abstract]	'
Increase in parent company distributable reserves	$1.60

ShareBased_Compensation_Expens

Share-Based Compensation Expense (Detail) (Share Options And Restricted Stock Units [Member], USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation expense	$11,876	$6,355	$32,139	$14,684
Tax benefit from share-based compensation expense	-3,502	0	-9,850	0
Total share-based compensation expense, net of tax	8,374	6,355	22,289	14,684
Selling, general and administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation expense	9,354	5,330	25,898	11,967
Research and development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation expense	1,931	681	4,453	1,718
Cost of product sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share-based compensation expense	$591	$344	$1,788	$999

WeightedAverage_Assumptions_Us

Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model Which Was Used to Estimate Grant Date Fair Value per Share (Detail) (Employee Stock Option [Member], USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Stock Option [Member]	'	'	'	'
Schedule of Weighted Average Assumptions for Fair Values of Stock Options[Line Items]	'	'	'	'
Shares underlying options granted (in shares)	105	1,157	1,277	2,077
Weighted-average grant date fair value (in dollars per share)	$37.17	$23.13	$28.49	$25.23
Weighted-average volatility	57.00%	64.00%	59.00%	64.00%
Weighted-average expected term (years)	'4 years 4 months 24 days	'4 years 2 months 12 days	'4 years 4 months 24 days	'4 years 7 months 6 days
Range of risk-free rates, minimum	1.00%	0.50%	0.50%	0.50%
Range of risk-free rates, maximum	1.40%	0.60%	1.40%	1.10%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

ShareBased_Compensation_Restri

Share-Based Compensation Restricted Units (Details) (Restricted Stock Units (RSUs) [Member], USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Units granted	46	550	568	1,002
Weighted average grand date fair value (in dollars per share)	$80.35	$46.83	$60.73	$48.98

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized compensation cost related to unvested stock option and RSUs	$58.30
Weighted-average period expected to be recognized	'2 years 8 months 24 days
Restricted Stock Units (RSUs) [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Vesting period	'4 years
Unrecognized compensation cost related to unvested stock option and RSUs	$46.30
Weighted-average period expected to be recognized	'3 years 0 months 0 days

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013
Related Party Transactions [Abstract]	'
Number of shares sold in a secondary offering	5.4
Gross proceeds to selling shareholder	$314.40
Expenses in connection with secondary offering	$0.50

Segment_and_Other_Information_1

Segment and Other Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
	Segment
Segment Reporting [Abstract]	'
Number of operating business segment	1

Summary_of_Total_Revenues_Deta

Summary of Total Revenues (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue from External Customer [Line Items]	'	'	'	'
Product sales, net	$230,386	$174,130	$631,602	$398,585
Royalties and contract revenues	1,774	1,385	5,047	3,691
Total revenues	232,160	175,515	636,649	402,276
Xyrem [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Product sales, net	153,664	102,615	404,932	265,149
Erwinaze And Erwinase [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Product sales, net	44,078	31,652	130,754	37,660
Prialt [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Product sales, net	11,046	5,413	20,726	20,491
Psychiatry [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Product sales, net	10,679	21,032	40,093	58,518
Other [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Product sales, net	$10,919	$13,418	$35,097	$16,767

Summary_of_Total_Revenues_Attr

Summary of Total Revenues Attributed to Geographic Sources (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenues	$232,160	$175,515	$636,649	$402,276
United States [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenues	209,299	159,947	577,484	375,658
Europe [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenues	19,332	12,164	46,769	21,252
Other [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenues	$3,529	$3,404	$12,396	$5,366

Summary_of_Revenues_from_Custo

Summary of Revenues from Customers Representing at Least 10% of Total Revenues (Detail) (Sales Revenue, Goods, Net [Member])	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Express Scripts [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Percentage of total revenues	66.00%	58.00%	63.00%	66.00%
Accredo Health Group, Inc. [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Percentage of total revenues	16.00%	14.00%	17.00%	7.00%

Total_LongLived_Assets_by_Loca

Total Long-Lived Assets by Location (Detail) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'
Long lived assets	$12,060	[1]	$7,281	[1]
Ireland [Member]	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'
Long lived assets	4,057		2,437
United States [Member]	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'
Long lived assets	7,394		4,451
Other [Member]	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'
Long lived assets	$609		$393
[1]	Long-lived assets consist of property and equipment.

Restructuring_Details

Restructuring (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Restructuring Reserve [Roll Forward]	'	'
Balance, beginning of period	$1,227	'
Costs incurred during the period	1,457	'
Cash payments	-2,376	'
Balance, end of period	308	'
Facility Closing [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Cash payments	-104	'
Balance, end of period	308	'
One-time Termination Benefits [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Balance, beginning of period	1,227	'
Costs incurred during the period	3,834	'
Cash payments	-2,272	'
Balance, end of period	0	'
Selling, general and administrative [Member] | Facility Closing [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Costs incurred during the period	412	'
Selling, general and administrative [Member] | One-time Termination Benefits [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Costs incurred during the period	$1,045	$2,180

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2012		Sep. 30, 2012		Dec. 31, 2012
					Women's Health Business [Member]
					women_health_product
					employee
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'		'		'
Women's health products purchased by Meda	'		'		6
The number of employees offered positions by purchaser of the discontinued operation	'		'		60
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]	'		'		'
Product sales, net	$8,086		$19,277		'
Loss from discontinued operations	($386)	[1]	($6,908)	[1]	'
[1]	There was no income tax on the loss from discontinued operations.

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Taxes [Line Items]	'	'	'	'
Income tax provision	$18,335	$12,856	$59,574	$24,966
Effective income tax rate	19.60%	27.70%	27.00%	20.80%
Ireland [Member]	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Effective statutory income tax rate	'	'	12.50%	'